INNOCAN PHARMA Corp
corporate_fare Company Profile
INNOCAN PHARMA Corp (OTC:INNPF) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 4 items for INNPF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-05-27, rated 7/10. Across its 4 most recent items scored 7 or higher, the top rating is 9/10, with 2 rated 8 or above. Recent SEC coverage for INNPF spans F-1/A, F-1.
Recent high-impact activity:
- Innocan Pharma Reports Q1 Revenue Up 29.7% Sequentially, Defers US IPO
- INNOCAN PHARMA Files F-1/A for Highly Dilutive IPO to Fund Pre-Clinical CBD Drug Development Amidst Going Concern Warning
- Innocan Pharma Reports 9.6% Revenue Decline to $26.6M in 2025, Eyes U.S. Public Offering
- INNOCAN PHARMA Files F-1 for Highly Dilutive Unit Offering to Fund CBD Drug Development Amidst Going Concern
Short Interest & Short Volume
40.53 days to coverFINRA reported short interest of 1,621 shares in INNPF as of the September 15, 2026 settlement, a 10706.7% increase from the prior period — about 40.5 days to cover at its recent average daily volume. On October 2, 2026, 14.9% of INNPF volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
INNPF files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.